How much does Haemostatix Limited make?

Haemostatix Limited reported revenue of £0 and a loss of £106k in the year to 31 Dec 2025, according to its accounts filed at Companies House.

Is Haemostatix Limited profitable?

No — Haemostatix Limited reported a loss of £106k in the year to 31 Dec 2025.

Company No. 04698400 · Incorporated 14 Mar 2003

Haemostatix Limited

Registered name: HAEMOSTATIX LIMITED

Part of Permira VIII Investment Platform Limited group

Haemostatix Limited made £0 revenue and a £106k loss in the year to 31 Dec 2025.

Haemostatix Limited’s revenue was £0 in the year to 31 Dec 2025, with a loss of £106k. The company is classified under “research and experimental development on biotechnology” and is based in Guildford; we hold 3 years of its filed accounts.

Full profit & loss filedSIC 72110Research and experimental development on biotechnology

Status: Active
Location: Guildford
Age: 23 yrs · since 2003
Type: Private Limited Company

Latest accounts · year to 31 Dec 2025

Key figures

Revenue

£0

Growth —

Profit

−£106k

Growth —

Profit margin

—

Employees

—

Change —

Profit / employee

—

Profitable streak

0yrs

Consecutive profitable years in our data

3 filed years

Financial history

Multi-year financials, oldest to newest
Year to	31 Dec 2023	31 Dec 2024	31 Dec 2025
Disclosure	Profit & loss	Profit & loss	Profit & loss
Profit & loss
Revenue (turnover)	£0	£0	£0
Operating profit	−£105k	−£115k	−£106k
Profit before tax	−£105k	−£115k	−£106k
Profit after tax	−£105k	−£115k	−£106k
Profit (best available)	−£105k	−£115k	−£106k
Employees (average)	—	—	—
Ratios
Profit margin	—	—	—
Balance sheet — indirect signals, not revenue
Net assets	—	—	—
Source	Accounts · bulk data Oct 2025	Accounts · bulk data Oct 2025	Accounts · bulk data Oct 2026

Derived from the latest filing

How the business works

Profit margin: —; Profit ÷ revenue.
Gross margin: —; Gross profit ÷ revenue. High for software and services.
Revenue per employee: —; Revenue ÷ average employees.
Profit per employee: —; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: —; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: —; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: —; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: —; Now —
Cash at bank: —; Now —
Headcount: —; Now —
Deferred income: —; Now —
Fixed assets: —; Now —

Corporate ownership

Group structure

Ownership chain

Permira VIII Investment Platform Limitedultimate parent75–100%
Eightplatform V Limited75–100%
Eden Topco Limited75–100%
Eden Holdco 1 Limited75–100%
Eden Holdco 2 Limited75–100%
Eden Holdco 3 Limited75–100%
Eden Acquisitionco Limited75–100%
Ergomed Group Limited75–100%
Haemostatix Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (4)

Adamas Consulting Group LimitedFigures not disclosed
Ergomed Clinical Research LimitedFigures not disclosed
Ergomed US Holdings LimitedFigures not disclosed
Primevigilance LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Sources

Companies House profile Filing history & original accounts

Latest figures from accounts for the year to 31 Dec 2025 (profit −£106k), from the Companies House accounts bulk data published Oct 2026. Spotted an error? Request a correction.

Updated from Companies House on 22 Oct 2026